The metastatic colorectal cancer drug treatment landscape has advanced considerably, with a growing range of targeted therapies, immunotherapies, and innovative agents now complementing standard chemotherapy. The mCRC treatment paradigm is structured across multiple lines of therapy. First-line (1L) treatment typically involves combination chemotherapies such as FOLFOX, FOLFIRI, or CAPEOX, along with anti-angiogenic agents or targeted therapies like VECTIBIX and ERBITUX, with or without chemotherapy. More recently, KEYTRUDA and BRAFTOVI (used with ERBITUX and mFOLFOX6) have also gained approval for use in the 1L setting.
Second-line (2L) mCRC therapies build ...
